These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
204 related articles for article (PubMed ID: 25463410)
1. Breast magnetic resonance imaging performance: safety, techniques, and updates on diffusion-weighted imaging and magnetic resonance spectroscopy. Melsaether A; Gudi A Top Magn Reson Imaging; 2014 Dec; 23(6):373-84. PubMed ID: 25463410 [TBL] [Abstract][Full Text] [Related]
2. Safety of magnetic resonance contrast media: a review with special focus on nephrogenic systemic fibrosis. Haneder S; Kucharczyk W; Schoenberg SO; Michaely HJ Top Magn Reson Imaging; 2015 Feb; 24(1):57-65. PubMed ID: 25654421 [No Abstract] [Full Text] [Related]
4. Nephrogenic systemic fibrosis and gadolinium: a cautionary tale in the molecular imaging era. Wang SC J Med Imaging Radiat Oncol; 2008 Aug; 52(4):305-6. PubMed ID: 18811752 [No Abstract] [Full Text] [Related]
5. Re: chemical structure and stability of gadolinium chelates. Idée JM; Port M; Corot C Radiographics; 2009 Nov; 29(7):2099. PubMed ID: 19926764 [No Abstract] [Full Text] [Related]
13. Free gadolinium is a likely trigger of nephrogenic systemic fibrosis. Abraham JL; Edward M AJR Am J Roentgenol; 2009 Oct; 193(4):W354; author reply W355. PubMed ID: 19770307 [No Abstract] [Full Text] [Related]
14. Contrast-enhanced magnetic resonance angiography of the peripheral arteries: technique, tips, pitfalls and problems. Welman CJ; Harrison C; Low RS J Med Imaging Radiat Oncol; 2013 Apr; 57(2):125-40. PubMed ID: 23551769 [TBL] [Abstract][Full Text] [Related]
15. Gadolinium-induced NSF claim resolved in favor of plaintiff. Ball JB; Samaritan G J Med Assoc Ga; 2012; 101(3):32-3. PubMed ID: 23198628 [No Abstract] [Full Text] [Related]
16. Gadolinium-based contrast agents and nephrogenic systemic fibrosis: why did it happen and what have we learned? Weinreb JC; Abu-Alfa AK J Magn Reson Imaging; 2009 Dec; 30(6):1236-9. PubMed ID: 19938035 [TBL] [Abstract][Full Text] [Related]
18. Correction to the relative risk calculation for gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis. Jain R; Levine M Radiology; 2010 Apr; 255(1):307-8; author reply 308. PubMed ID: 20308469 [No Abstract] [Full Text] [Related]
19. Nephrogenic systemic fibrosis and gadolinium-enhanced magnetic resonance imaging: does a US Food and Drug Administration alert influence practice patterns in CKD? Martin DR Am J Kidney Dis; 2010 Sep; 56(3):427-30. PubMed ID: 20728788 [No Abstract] [Full Text] [Related]
20. Gadolinium and nephrogenic systemic fibrosis. Runge VM AJR Am J Roentgenol; 2009 Apr; 192(4):W195-6; discussion W197. PubMed ID: 19304681 [No Abstract] [Full Text] [Related] [Next] [New Search]